Tetracycline Inhibitors
2 drugsAbout Tetracycline
Tetracycline is a broad-spectrum polyketide antibiotic that inhibits bacterial protein synthesis. While its precise molecular mechanism is still being investigated, it remains a valuable therapeutic agent against a wide range of bacterial infections.
Tetracycline represents a well-established drug target with a history of clinical use. There is currently no genetic evidence directly linking Tetracycline to specific diseases, but its clinical efficacy supports continued development.
Two FDA-approved drugs include Tetracycline: PYLERA and BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE. Both drugs are small molecules and are classified within the 'other' therapeutic area.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Small Intestine Bacterial Overgrowth with only 1 trials.
Top Drugs
The competitive landscape includes LABS JUVISE and PH HEALTH, each with approved drugs.
The presence of only two companies suggests a relatively unconcentrated market with potential entry opportunities.
Drug Modality Landscape
Modalities
Routes of Administration
Tetracycline is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like modified peptides or biologics could provide a competitive advantage.
Clinical Trials 157 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 26 | 22 | 1 | 3 | 96% |
| Phase 2 | 38 | 21 | 5 | 12 | 81% |
| Phase 3 | 33 | 27 | 3 | 3 | 90% |
| Phase 4 | 60 | 43 | 7 | 10 | 86% |
Top Sponsors
By Modality
Top Conditions
Drug Approval Timeline (2006 - 2023)
Helicobacter pylori Infection
The first drug was approved in 2006 (PYLERA), with the most recent approval in 2023.
The 18-year span between approvals suggests sustained interest, but also potential saturation in the therapeutic area.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 96 clinical trials targeting Tetracycline.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities